Compare GSK plc (GSK) vs Wipro Limited (WIT) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

WIT trades at $1.82, down 1.09% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net income of $131.35 billion for 2025 with a 14.25% margin, though recent quarters show earnings misses. Revenue guidance remains cautious amid client spending constraints, while strategic AI partnerships aim to drive future growth.

The outlook is mixed: valuation ratios appear reasonable with a P/E of 13.82, but weak near-term revenue visibility and consecutive earnings misses pose risks. Analyst sentiment is cautious with only 19% buy ratings. Upside depends on AI initiatives translating to sustained growth, while downside risks include sector-wide demand pressures.